Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $39.86 Consensus PT from Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been given a consensus recommendation of “Buy” by the nine brokerages that are covering the stock, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $39.86.

A number of equities research analysts have recently weighed in on the company. Wolfe Research assumed coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They set an “outperform” rating and a $20.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a report on Friday, February 7th. Finally, Wedbush reissued an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research note on Friday, March 7th.

Oruka Therapeutics Trading Down 3.5 %

Shares of ORKA opened at $11.47 on Wednesday. The company has a fifty day simple moving average of $12.09. Oruka Therapeutics has a 52-week low of $9.44 and a 52-week high of $31.13. The company has a market cap of $429.45 million, a P/E ratio of -1.83 and a beta of 0.67.

Oruka Therapeutics (NASDAQ:ORKA) last announced its earnings results on Thursday, March 6th. The company reported ($0.49) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.19. On average, sell-side analysts forecast that Oruka Therapeutics will post -3.41 EPS for the current fiscal year.

Insider Buying and Selling at Oruka Therapeutics

In other Oruka Therapeutics news, major shareholder Venrock Healthcare Capital Par bought 8,971 shares of the stock in a transaction that occurred on Wednesday, February 12th. The stock was acquired at an average cost of $11.86 per share, with a total value of $106,396.06. Following the purchase, the insider now owns 4,044,684 shares in the company, valued at $47,969,952.24. This trade represents a 0.22 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders bought 98,339 shares of company stock valued at $1,128,456. Corporate insiders own 22.67% of the company’s stock.

Institutional Trading of Oruka Therapeutics

A number of large investors have recently bought and sold shares of ORKA. The Manufacturers Life Insurance Company bought a new stake in shares of Oruka Therapeutics during the third quarter worth $1,037,000. FMR LLC bought a new position in Oruka Therapeutics during the 3rd quarter worth about $114,763,000. Great Point Partners LLC bought a new position in shares of Oruka Therapeutics during the third quarter worth about $12,614,000. Braidwell LP bought a new position in shares of Oruka Therapeutics during the third quarter worth about $12,640,000. Finally, Janus Henderson Group PLC bought a new position in shares of Oruka Therapeutics during the third quarter worth about $5,840,000. 56.44% of the stock is owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.